BioTissue Inc, a subsidiary of TissueTech, uses its proprietary cyro-preservation technologies to produce amniotic membrane tissue products with properties that promote anti-inflammatory, anti-scarring and anti-angiogenic actions. Patented cryopreservation methods support the development of a new generation of ocular surface tissue therapies designed to accelerate the regeneration of damaged tissue while reducing recipient discomfort associated with ocular surface reconstruction. The firm offers the only commercially available amniotic membrane that preserves the native integrity, activity, and function exhibited by the tissue in utero for ocular surface wound repair and wound healing. The Company's two commercialized products are targeted to restore eye surface damages caused by corneal or conjunctival ulcers, chemical burns, and pterygium, etc. AmnioGraft improves various surgical outcomes for eye surgeries, including pterygium, conjuntivochalasis, corneal defects, high-risk trabeculectomies, leaking glaucoma blebs, chemical burns, Stevens Johnson syndrome, and strabismus. The company also has a pipeline that includes several stem-cell therapies and novel medical devices at different stages of development. The Company's goal is to expand the therapeutic actions of its tissue-engineered products to other body sites in the future.
